Replies to post #20823 on Radient Pharmaceuticals Corporation fka RXPC

[guardiangel]

DC Man Nice Post

dcspka Wednesday, 04/16/14 10:21:57 PM
Re: lakeshore555 post# 20822
Post # of 20823
No one files an 8K regarding a Creeping Takeover. They will let you know when the right combination of events has fallen into place:

-Patents
-Finances
-stock accumulation
-etc.


Wolf Says ahoooooo


Only 20 people can own the 4.5 billion shares with a 4.999 percent share ownership. There is one I know with 1 percent. The other 9 percent could be 8 other investors with one percent.... That makes only 18 investors that can own 4.999 percent. At this time there are 12 serious investors a/k/a creeping takeover group,and 6 lenders...That is a 60/30/10 mix...Last week I stated that the takeover group was at 52 percent with 5 percent of the shares not released..That made 57 percent..I believe they are getting close to the 60 percent goal.Look for the bid and ask to go up again in order to collect some more loose shares from some flippers..

Columbo Says" Just One More Thing"

I like that number 18..That is the same amount of investors that started provista Dx via William..William is one of those 18 you understand.

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.

Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
18

1. Issuer's Identity
CIK (Filer ID Number) Previous Names
X None
Entity Type
0001539252
X Corporation
Limited Partnership
Limited Liability Company
General Partnership
Business Trust
Other (Specify)

Name of Issuer
Provista Diagnostics Inc.
Jurisdiction of Incorporation/Organization
DELAWARE
Year of Incorporation/Organization
Over Five Years Ago
X Within Last Five Years (Specify Year) 2009
Yet to Be Formed

2. Principal Place of Business and Contact Information
Name of Issuer
Provista Diagnostics Inc.
Street Address 1 Street Address 2
6225 NORTH 24TH STREET, SUITE 150
City State/Province/Country ZIP/PostalCode Phone Number of Issuer
PHOENIX ARIZONA 85016 [phone]

3. Related Persons
Last Name First Name Middle Name
Reese David
Street Address 1 Street Address 2
6225 NORTH 24TH STREET, SUITE 150
City State/Province/Country ZIP/PostalCode
PHOENIX ARIZONA 85016
Relationship: X Executive Officer X Director Promoter

Clarification of Response (if Necessary):
President and Chief Executive Officer

http://www.sec.gov/Archives/edgar/data/1539252/000153925212000005/xslFormDX01/primary_doc.xml

[guardiangel]

DCSPKA You Said Provista

Here is some latest development. In threes? What is next?

Diagnostics Secures $6MM Series B Financing Apr 16, 2014 4:59 am Eastern Time

Provista Diagnostics, Inc., a privately held molecular diagnostics company developing and commercializing diagnostic, prognostic and predictive tests for cancers affecting women, today announced completion of its Series B financing. The $6.0 million Series B financing was fulfilled by the company’s existing investors.

This funding will enable the company to expand the commercial market development for dtectDx-Breast, as well as pursue additional clinical trials as the company works toward 510K regulatory clearances for the assay.

“We are grateful to our shareholders for their continuing support of the company and its vision, especially now, as we navigate through this important period,” said David Reese, Ph.D., President and CEO. “We have made great progress over the past two years, and this investment reflects the continued belief in our science and technology innovations.”

To date, Provista Diagnostics has raised $19.5 million, including the current Series B financing and $13.5 million through Series A financings in 2012 and 2013.

About Provista
Provista Diagnostics, Inc. is a privately held molecular diagnostics company focused on developing and commercializing through its dtectDx platform, proprietary diagnostic, prognostic and predictive tests for cancers affecting women, including breast and ovarian. Provista also offers diagnostic testing and clinical laboratory services to the pharmaceutical and biotechnology industries through Provista Companion Diagnostics, a CLIA-accredited and GLP capable laboratory, licensed in 49 states to perform human clinical testing. More information about Provista and Provista Companion Diagnostics is available at www.provistadx.com and www.provistacdx.com.

The securities sold in the private placement have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (SEC) or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any stock in Provista Diagnostics, Inc.

Safe Harbor Statement
Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Provista’s actual results may differ materially due to a number of factors, many of which are beyond Provista’s ability to predict or control, including among others, viability and effectiveness of our sales approach and overall marketing strategies, the outcome of development or regulatory review of our products, commercial success or acceptance by the medical community, competitive responses, our ability to raise additional capital, and the ability to successfully file a registration statement with the SEC. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. Provista operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Provista undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.

http://www.provistadx.com/provistaDx-News.html

[lakeshore555]

I asked "But will Radient file an 8-K for the class action?"

"If they do -- what does that say about the UNI and GCDx licensing agreements? I suggest that it means Radient is releasing 8-K's when they feel they should, and not holding any back.... which means the GCDx agreement was never renewed... but does that also mean the UNI agreement was cancelled, since there was no 8-K for the $80,000?

And if they don't -- that lends credence to the assertion that Radient is selectively filing 8-K's and is being secretive. Interesting. "

Nobody is saying there should be an 8-K for a creeping takeover. But I thought this rumor was about a creeping backdoor merger? Certainly, someone would file an 8-K for a merger.

[Gold Seeker]

Dcspka, give us just one single example of an secret "creeping takeover".